Table 5

Summary of efficacy outcomes in patients treated with lenalidomide monotherapy

Median values, moOverall, N = 222CR + PR, n = 58CR + PR + MR, n = 98
Progression-free survival 4.9* 14.5 10.4 
Time to progression 5.2 14.5 10.4 
Overall survival 23.2 33.9 28.0 
Median values, moOverall, N = 222CR + PR, n = 58CR + PR + MR, n = 98
Progression-free survival 4.9* 14.5 10.4 
Time to progression 5.2 14.5 10.4 
Overall survival 23.2 33.9 28.0 

CR indicates complete response; MR, minimal response; and PR, partial response.

*

Patients who had disease progression or died: 73%.

Patients who had disease progression: 69%.

Patients who died: 60%.